Skip to Main
Investment Banking

Oppenheimer Acted as U.S. Placement Agent for ESSA Pharma, Inc.

  • Oppenheimer & Co. Inc.
  • September 26, 2019
tombstone

ESSA is a pharmaceutical company focused on developing novel and proprietary therapies for the treatment of castration-resistant prostate cancer ("CRPC") in patients whose disease is progressing despite treatment with current therapies. ESSA's proprietary "aniten" compounds bind to the N-terminal domain of the androgen receptor ("AR"), inhibiting AR driven transcription and the AR signaling pathway in a unique manner which bypasses the drug resistance mechanisms associated with current anti-androgens. The Company is currently progressing IND-enabling studies and expects to file an IND with the FDA for EPI-7386 in the first calendar quarter of 2020.

For more information please contact:

Healthcare Investment Banking                                                     Equity Capital Markets
Michael A. Margolis, R.Ph.                                                             Peter Bennett
Co-Head of Healthcare Investment Banking                                   Head of Equity Capital Markets
212-667-7622                                                                                212-667-6285
MichaelA.Margolis@opco.com                                                        Peter.Bennett@opco.com


Stefan Loren, PhD
Managing Director
858-202-3880
Stefan.Loren@opco.com

DISCLOSURES

This notice is provided for informational purposes only, and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.

This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.

Oppenheimer and Oppenheimer Asset Management Inc (OAM) are principle subsidiaries of Oppenheimer Holdings Inc., and provide a full range of wealth management, securities brokerage, capital markets, and investment banking services to high-net worth individuals, families, corporate executives, businesses and institutions. The Firm creates integrated financial strategies tailored to each client’s goals. For over 130 years of operation, Oppenheimer has emphasized customer service, integrity and intellectual objectivity.

2019 Oppenheimer & Co. Inc. Transacts Business on all Principal Exchanges and Member SIPC 2721353.1